PHA Live is a monthly series of Facebook Live events and webinars that provides an opportunity for those affected by pulmonary hypertension (PH) to hear from experts on health, wellness, science and research topics. Recordings of PHA Live events will become available on this page within three business days of the original program.
PHA Research Room Findings
Thursday, July 29 at 3:30 p.m. EDT
Join the Pulmonary Hypertension Association (PHA) for the PHA Live event “PHA Research Room Findings” on Thursday, July 29 at 3:30 p.m. EDT.
PHA Research Room, PHA’s research project providing pulmonary hypertension (PH) patients the opportunity to participate in clinical research studies, is part of PHA’s International PH Conference and Scientific Sessions — the world’s largest gathering of people living with PH. Ten research teams and more than 200 attendees participated in PHA Research Room studies at the 2018 Conference.
In this PHA Live event, scientists and clinicians will present findings from the 2018 PHA Research Room. Learn about pulmonary arterial hypertension biomarkers, patient survey results from support group therapy, an outcomes risk assessment tool for PH patients and barriers to exercise therapy in PH.
Interested participants may email us any questions they would like addressed by Tuesday, July 27.
About the Speakers
Raymond Benza, M.D.
Raymond L. Benza, M.D., is a professor of medicine at The Ohio State University in Columbus, Ohio, where he serves as the director of the Division of Cardiovascular Diseases and as an adjunct professor in the School of Biomedical Engineering at Carnegie Mellon University in Pittsburgh, Pa. Dr. Benza is also the Bob and Corrine Frick Endowed Chair of Heart Failure at The Ohio State University Wexner Medical Center in Columbus, Ohio. His primary clinical interests are the evaluation and treatment of advanced congestive heart failure, cardiac transplantation and pulmonary arterial hypertension (PAH). He also has provided mechanical support to the REVEAL registry, the largest clinical dataset of PAH in the world, in which he co-developed the REVEAL calculator which is currently the gold standard risk stratification tool for patients with PAH.
Thomas Cascino, M.D.
Thomas Cascino, M.D., is an advanced heart failure and transplant cardiologist. He is also a health services researcher interested in health care delivery, health equity and disparities in access to therapies for patients with PH and heart failure. His current work is focused on the identification of barriers in access to health care, understanding disparities in the use of therapies such as exercise rehabilitation and optimizing the implementation of exercise rehabilitation through novel modes of delivery.
Paresh Giri, M.D.
Paresh Giri, M.D., is an associate professor of medicine and medical director of Respiratory Care Services and the Pulmonary Hypertension Program at Loma Linda University Medical Center. His clinical and research interests include PH, high altitude pulmonary vascular disease, novel therapeutics in PAH and the use of ultrasound in critical care.
As founder and director of the PH program at Loma Linda University, he has led the program to become a PH Care Center (PHCC) Regional Care Program (RCP). He is involved in multiple clinical studies involving PH therapies and is active in local support groups of PHA.
Kara Goss, M.D. (Moderator)
Kara Goss, M.D., is an assistant professor of medicine and pediatrics at the University of Texas Southwestern and specializes in PH. Her research program is focused on the effects of preterm birth on the heart and lungs later in life. Her program also performed the first catherization-based studies to demonstrate PH development years after preterm birth in some individuals.
Mike Solomon, M.D., M.B.A.
Mike Solomon, M.D., M.B.A., is a senior research physician and senior staff member of the Critical Care Medicine Department of the Clinical Center and Cardiovascular Branch of the National Heart, Lung, and Blood Institute (NHLBI) at the National Institutes of Health (NIH). He is also the co-director of the PAH Program at the Clinical Center, an integrative bench-to-bedside research program that seeks to enhance the understanding of the underlying mechanisms that lead to PAH and to promote novel therapeutics that improve patient quality of life.
Paul Yu, M.D., Ph.D.
Paul Yu, M.D., Ph.D., is an associate professor of medicine at Harvard Medical School and a physician in cardiovascular medicine at Brigham and Women’s Hospital (BWH). He joined BWH as a collaborative basic and translational researcher in PAH. The overall goal of his work is to understand how developmental growth factor and signaling pathways regulate pulmonary vascular and bone development and maintenance and contribute to the body’s response to injury or inflammatory stress.
PHA thanks Bayer for its Platinum Sponsorship and Janssen Pharmaceuticals, Inc. for its Diamond Sponsorship of the PHA Connects fund, which provides support to this PHA Live event.
Watch Previous PHA Live Events
PHA thanks Janssen Pharmaceuticals, Inc. for its diamond sponsorship and Bayer for its platinum sponsorship of the PHA Connects fund, which provides support to this PHA Live event.